Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data

Anne J Kugler,1 Michael L Thiman2 1Department of Pharmacy Practice and Administration, Western University of Health Sciences College of Pharmacy, Pomona, CA, USA; 2Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA, USA Abstract: Dulaglutide is...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kugler AJ, Thiman ML
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	GLP-1 RA glucagon-like peptide-1 receptor agonist antidiabetic drugs diabetes mellitus injectable incretin Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/96492cf1c8914c96864b80eead4d4fe9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:96492cf1c8914c96864b80eead4d4fe9
record_format	dspace
spelling	oai:doaj.org-article:96492cf1c8914c96864b80eead4d4fe92021-12-02T02:07:00ZEfficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data1178-7007https://doaj.org/article/96492cf1c8914c96864b80eead4d4fe92018-05-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-profile-of-once-weekly-dulaglutide-in-type-2-diabe-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Anne J Kugler,1 Michael L Thiman2 1Department of Pharmacy Practice and Administration, Western University of Health Sciences College of Pharmacy, Pomona, CA, USA; 2Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA, USA Abstract: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from -0.78% to –1.64% over 52–104 weeks, and it consistently outperformed each of these agents. As an add-on therapy, dulaglutide provided additional A1c lowering of –1.4% to –1.44% over monotherapy with glimepiride or glargine at 24 and 28 weeks, respectively. Dulaglutide outperformed exenatide when added to a regimen of metformin with pioglitazone as well as glargine when added to a regimen of metformin with glimepiride. Dulaglutide was shown to be non-inferior to liraglutide when added to metformin. In all AWARD studies other than when compared to liraglutide, dulaglutide at full strength resulted in significantly more patients achieving their A1c goal. Recent class-wide meta-analyses indicate that the incidence of commonly experienced gastrointestinal (GI) side effects is dose dependent, and nausea and vomiting are less common in longer-acting agents such as dulaglutide, but diarrhea may be more common. Pooled data have shown no increased risk of serious side effects such as pancreatitis or neoplasm with the use of dulaglutide. Given the evidence supporting liraglutide’s cardiovascular benefits, the highly anticipated REWIND trial will have a significant impact on the future place in the therapy of dulaglutide. Keywords: GLP-1 RA, glucagon-like peptide-1 receptor agonist, antidiabetic drugs, diabetes mellitus, injectable, incretinKugler AJThiman MLDove Medical PressarticleGLP-1 RAglucagon-like peptide-1 receptor agonistantidiabetic drugsdiabetes mellitusinjectableincretinSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 11, Pp 187-197 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	GLP-1 RA glucagon-like peptide-1 receptor agonist antidiabetic drugs diabetes mellitus injectable incretin Specialties of internal medicine RC581-951
spellingShingle	GLP-1 RA glucagon-like peptide-1 receptor agonist antidiabetic drugs diabetes mellitus injectable incretin Specialties of internal medicine RC581-951 Kugler AJ Thiman ML Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
description	Anne J Kugler,1 Michael L Thiman2 1Department of Pharmacy Practice and Administration, Western University of Health Sciences College of Pharmacy, Pomona, CA, USA; 2Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA, USA Abstract: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from -0.78% to –1.64% over 52–104 weeks, and it consistently outperformed each of these agents. As an add-on therapy, dulaglutide provided additional A1c lowering of –1.4% to –1.44% over monotherapy with glimepiride or glargine at 24 and 28 weeks, respectively. Dulaglutide outperformed exenatide when added to a regimen of metformin with pioglitazone as well as glargine when added to a regimen of metformin with glimepiride. Dulaglutide was shown to be non-inferior to liraglutide when added to metformin. In all AWARD studies other than when compared to liraglutide, dulaglutide at full strength resulted in significantly more patients achieving their A1c goal. Recent class-wide meta-analyses indicate that the incidence of commonly experienced gastrointestinal (GI) side effects is dose dependent, and nausea and vomiting are less common in longer-acting agents such as dulaglutide, but diarrhea may be more common. Pooled data have shown no increased risk of serious side effects such as pancreatitis or neoplasm with the use of dulaglutide. Given the evidence supporting liraglutide’s cardiovascular benefits, the highly anticipated REWIND trial will have a significant impact on the future place in the therapy of dulaglutide. Keywords: GLP-1 RA, glucagon-like peptide-1 receptor agonist, antidiabetic drugs, diabetes mellitus, injectable, incretin
format	article
author	Kugler AJ Thiman ML
author_facet	Kugler AJ Thiman ML
author_sort	Kugler AJ
title	Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
title_short	Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
title_full	Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
title_fullStr	Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
title_full_unstemmed	Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
title_sort	efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/96492cf1c8914c96864b80eead4d4fe9
work_keys_str_mv	AT kugleraj efficacyandsafetyprofileofonceweeklydulaglutideintype2diabetesareportontheemergingnewdata AT thimanml efficacyandsafetyprofileofonceweeklydulaglutideintype2diabetesareportontheemergingnewdata
_version_	1718402720367378432

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data

Ejemplares similares